---
title: "Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower"
nct_id: NCT00663325
overall_status: COMPLETED
phase: PHASE3
sponsor: Sanofi
study_type: INTERVENTIONAL
primary_condition: Hygiene
countries: Brazil
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00663325.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00663325"
ct_last_update_post_date: 2009-01-08
last_seen_at: "2026-05-12T06:49:17.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower

**Official Title:** Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Tangerina Mix

**NCT ID:** [NCT00663325](https://clinicaltrials.gov/study/NCT00663325)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Sanofi
- **Conditions:** Hygiene
- **Start Date:** 2007-12
- **CT.gov Last Update:** 2009-01-08

## Brief Summary

The purpose of this study is to demonstrate the safety of the gynecological formulation in normal and usual usage condition of Dermacyd Tina Gel Sweet Flower.

## Eligibility

- **Minimum age:** 10 Years
- **Maximum age:** 20 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Integral skin test in the region;

Exclusion Criteria:

* Lactation or gestational risk or gestation;
* Use of Anti-inflammatory or immunosuppression drugs 1 month before the study;
* Topical medication use at the region to be treated;
* Cutaneous disease or active gynecological disease which may interfere in study results;
* Personal history of allergic disease at the area to be treated;
* Allergic or atopic history;

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
```

## Arms

- **1** (EXPERIMENTAL) — Lactic acid in small quantity during 21 days

## Interventions

- **Lactic acid (Dermacid)** (DRUG) — Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.

## Primary Outcomes

- **Adverse events and their intensity and their association with the treatment** _(time frame: 21 days)_

## Locations (1)

- Sanofi-aventis, São Paulo, São Paulo, Brazil

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.sanofi-aventis|são paulo|são paulo|brazil` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00663325.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00663325*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*